Fragile X and Increased NT: A Prenatal Testing Case | MDster You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Case Discussion ](https://mdster.com/blog?category=case-discussion) 4. Fragile X Risk and Increased Nuchal Translucency: A Prenatal Case [ Case Discussion ](https://mdster.com/blog?category=case-discussion) Fragile X Risk and Increased Nuchal Translucency: A Prenatal Case =================================================================== How to counsel a patient when an FMR1 family history and an elevated NT call for different tests [ MDster Editorial Team ](https://mdster.com/about) · Oct 06, 2026 · 7 min read · 27 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Obstetrics & Gynecology ](https://mdster.com/blog?tag=obstetrics-gynecology) [ Case Discussion ](https://mdster.com/blog?tag=case-discussion) [ Genetic Counseling ](https://mdster.com/blog?tag=genetic-counseling) [ Fragile X Syndrome ](https://mdster.com/blog?tag=fragile-x-syndrome) [ Prenatal Genetics ](https://mdster.com/blog?tag=prenatal-genetics) [ Nuchal Translucency ](https://mdster.com/blog?tag=nuchal-translucency) ![Fragile X Risk and Increased Nuchal Translucency: A Prenatal Case](https://mdster.com/storage/blog/images/fragile-x-risk-and-increased-nuchal-translucency-a-prenatal-case.png) Share this article Share this post On this page 1. [ Two Findings, Two Diagnostic Questions ](#two-findings-two-diagnostic-questions) 2. [ The brother’s phenotype suggests fragile X ](#the-brothers-phenotype-suggests-fragile-x) 3. [ The NT finding requires a separate workup ](#the-nt-finding-requires-a-separate-workup) 4. [ Screening Cannot Answer Every Question ](#screening-cannot-answer-every-question) 5. [ Match each test to its target ](#match-each-test-to-its-target) 6. [ The 80-Repeat Result Changes Counseling ](#the-80-repeat-result-changes-counseling) 7. [ Inheritance is not the same as expansion ](#inheritance-is-not-the-same-as-expansion) 8. [ Choosing a Diagnostic Procedure ](#choosing-a-diagnostic-procedure) 9. [ Earlier information versus a different tissue sample ](#earlier-information-versus-a-different-tissue-sample) 10. [ Document a decision, not just a signature ](#document-a-decision-not-just-a-signature) 11. [ Key Points for Board Exams ](#key-points-for-board-exams) 12. [ Frequently Asked Questions ](#blog-faqs) 13. [ References ](#references-heading) On this page 1. [ Two Findings, Two Diagnostic Questions ](#two-findings-two-diagnostic-questions) 2. [ The brother’s phenotype suggests fragile X ](#the-brothers-phenotype-suggests-fragile-x) 3. [ The NT finding requires a separate workup ](#the-nt-finding-requires-a-separate-workup) 4. [ Screening Cannot Answer Every Question ](#screening-cannot-answer-every-question) 5. [ Match each test to its target ](#match-each-test-to-its-target) 6. [ The 80-Repeat Result Changes Counseling ](#the-80-repeat-result-changes-counseling) 7. [ Inheritance is not the same as expansion ](#inheritance-is-not-the-same-as-expansion) 8. [ Choosing a Diagnostic Procedure ](#choosing-a-diagnostic-procedure) 9. [ Earlier information versus a different tissue sample ](#earlier-information-versus-a-different-tissue-sample) 10. [ Document a decision, not just a signature ](#document-a-decision-not-just-a-signature) 11. [ Key Points for Board Exams ](#key-points-for-board-exams) 12. [ Frequently Asked Questions ](#blog-faqs) 13. [ References ](#references-heading) A reassuring cell-free DNA result could still miss this patient’s central concern: whether her fetus inherited a fragile X full mutation. At 11 weeks, a 32-year-old primigravida reports a brother with severe intellectual disability, autism, prominent ears, and a prominent jaw. Her fetal crown-rump length (CRL) is 45 mm, and nuchal translucency (NT) measures 3.2 mm. She wants diagnostic certainty but fears pregnancy loss from an invasive procedure. Two Findings, Two Diagnostic Questions -------------------------------------- ### The brother’s phenotype suggests fragile X Fragile X syndrome is the leading consideration, not a diagnosis established by appearance. If available, obtain the brother’s genetic report; other inherited neurodevelopmental disorders and chromosomal conditions remain possible. Regardless, this family history warrants genetic counseling and targeted maternal *FMR1* CGG-repeat testing. [\[1\]](#cite-1 "Reference [1]") *FMR1* disorders follow an X-linked inheritance pattern with markedly variable expression. A full mutation, usually more than 200 CGG repeats with abnormal methylation, reduces FMR1 expression; approximately 55–200 repeats constitute a premutation. Maternal transmission can expand a premutation into a full mutation, producing anticipation across generations. A father with a premutation transmits it to daughters, not sons, and paternal transmission does not ordinarily produce a full mutation. [\[1\]](#cite-1 "Reference [1]") ### The NT finding requires a separate workup An NT of 3.2 mm at a CRL of 45 mm is increased; confirm measurement quality with an appropriately trained sonographer. Increased NT raises concern for aneuploidy, other genetic conditions, and structural abnormalities, particularly cardiac disease. It does **not** establish fragile X syndrome or explain the brother’s phenotype. [\[2\]](#cite-2 "Reference [2]") The immediate differential therefore has two tracks: - **Familial neurodevelopmental risk:** an *FMR1* expansion is plausible; the brother’s molecular diagnosis would sharpen interpretation. - **Fetal increased-NT risk:** trisomy 21 and other chromosomal abnormalities require assessment, alongside later evaluation for structural anomalies. - **Coincidence:** the family history and NT may reflect unrelated processes; do not force them into one diagnosis. [\[1\]](#cite-1 "Reference [1]") For board examinations, the usual cellular origin of free trisomy 21 is maternal meiotic nondisjunction, most often in meiosis I. That mechanism is distinct from *FMR1* repeat expansion. [\[3\]](#cite-3 "Reference [3]") Screening Cannot Answer Every Question -------------------------------------- ### Match each test to its target Screening changes an estimated probability; diagnostic testing examines a sampled pregnancy for specified conditions. Maternal *FMR1* testing establishes her repeat status, but a positive result does not establish the fetus’s status. First-trimester combined screening and cell-free DNA (cfDNA) assess aneuploidy risk; neither substitutes for fetal *FMR1* repeat analysis. [\[4\]](#cite-4 "Reference [4]") OptionUseful answerImportant limitMaternal *FMR1* testIs she a premutation or full-mutation carrier?Does not diagnose the fetuscfDNA or combined screeningWhat is the estimated risk of common aneuploidies?Does not diagnose trisomy 21 or fragile XCVS or amniocentesisDoes the fetal sample have a specified genetic finding?Only conditions requested and technically assessed are addressed CfDNA is the most sensitive and specific screening option for common fetal aneuploidies, including trisomy 21, but even a low-risk result does not resolve an increased NT. A positive result requires counseling and an offer of diagnostic confirmation. After an enlarged NT, offer genetic counseling, diagnostic testing, and a detailed ultrasound evaluation rather than treating cfDNA as a definitive answer. [\[4\]](#cite-4 "Reference [4]") The 80-Repeat Result Changes Counseling --------------------------------------- ### Inheritance is not the same as expansion Suppose maternal testing identifies 80 CGG repeats on one *FMR1* allele. This is a **premutation**, not a maternal full-mutation diagnosis. Each pregnancy has a 50% chance of inheriting her expanded allele; whether an inherited premutation expands to a full mutation is a separate probability. Expansion risk depends on repeat length and AGG interruptions, so 80 repeats alone cannot support a precise fetal-risk estimate. [\[1\]](#cite-1 "Reference [1]") A male fetus with a full mutation is generally expected to have intellectual disability. A female fetus with a full mutation has less predictable expression, influenced partly by X-inactivation; neither fetal sex nor repeat count reliably predicts an individual child’s developmental course. Offer targeted prenatal *FMR1* diagnosis and discuss the patient’s own future risk of fragile X-associated primary ovarian insufficiency and tremor/ataxia syndrome. [\[1\]](#cite-1 "Reference [1]") Choosing a Diagnostic Procedure ------------------------------- ### Earlier information versus a different tissue sample At 11 weeks, chorionic villus sampling (CVS) offers an earlier answer from placental tissue; amniocentesis is generally performed from 15 weeks and samples amniotic fluid. Either can provide material for targeted *FMR1* repeat analysis and chromosomal testing. Discuss chromosomal microarray with genetics and maternal–fetal medicine specialists in light of the increased NT; it does not replace the specific *FMR1* assay. [\[5\]](#cite-5 "Reference [5]") - **If timing matters most:** offer CVS after confirming gestational age and arranging the requested laboratory analyses. - **If placental findings are ambiguous:** discuss whether amniocentesis is needed for clarification. Confined placental mosaicism can complicate chromosomal interpretation; *FMR1* methylation assessment on CVS may also require follow-up. [\[1\]](#cite-1 "Reference [1]") - **If avoiding an invasive procedure matters most:** noninvasive screening remains an option, provided she understands that it cannot establish fetal *FMR1* status or fully investigate increased NT. [\[4\]](#cite-4 "Reference [4]") > **Clinical Pearl:** Order the fetal *FMR1* assay explicitly. A chromosomal microarray or a low-risk cfDNA result must not be mistaken for a fragile X diagnosis. [\[1\]](#cite-1 "Reference [1]") ### Document a decision, not just a signature Before CVS or amniocentesis, use teach-back to document four elements: her understanding of what each requested assay can and cannot detect; benefits, uncertain findings, and procedural risks, including pregnancy loss; screening, later testing, and declining testing as alternatives; and a voluntary, non-directive choice. Avoid presenting a single miscarriage estimate as universally applicable: discuss the procedure-specific estimate and local operator experience. [\[6\]](#cite-6 "Reference [6]") Arrange detailed fetal anatomy assessment at 18–22 weeks regardless of the genetic result. Further cardiac evaluation should reflect the confirmed NT measurement, subsequent imaging, and specialist assessment. [\[7\]](#cite-7 "Reference [7]") Key Points for Board Exams -------------------------- - An affected brother suggests fragile X, but his phenotype alone cannot confirm the familial mutation. [\[1\]](#cite-1 "Reference [1]") - An 80-repeat maternal *FMR1* allele is a premutation; transmission and expansion are distinct risks. [\[1\]](#cite-1 "Reference [1]") - Increased NT and familial fragile X risk demand separate, coordinated investigations. [\[7\]](#cite-7 "Reference [7]") - cfDNA screens for common aneuploidies; fetal *FMR1* diagnosis requires a specifically requested assay on a diagnostic sample. [\[4\]](#cite-4 "Reference [4]") The best strategy is the one that answers **both** clinical questions at a time and procedural risk the patient accepts—not simply the test with the highest aneuploidy screening performance. [\[4\]](#cite-4 "Reference [4]") Frequently Asked Questions ---------------------------- ### Does a low-risk cfDNA result rule out fragile X syndrome in this pregnancy? No. Standard cfDNA aneuploidy screening does not replace targeted fetal *FMR1* repeat analysis. [\[4\]](#cite-4 "Reference [4]") ### Does an 80-repeat maternal allele mean the fetus has fragile X syndrome? No. It identifies a maternal premutation. The fetus must inherit that allele and it must expand to a full mutation for the usual fragile X syndrome mechanism. [\[1\]](#cite-1 "Reference [1]") ### Why might amniocentesis follow an FMR1 result from CVS? CVS can establish repeat size, but an uncertain methylation result may require confirmation using amniotic fluid cells. [\[1\]](#cite-1 "Reference [1]") ### If fetal genetic testing is negative, is follow-up ultrasound still necessary? Yes. An increased NT warrants detailed structural assessment even when testing for the selected genetic conditions is negative. [\[7\]](#cite-7 "Reference [7]") References (9) ------------------ 1. 1. [ www.ncbi.nlm.nih.gov/sites/books/NBK1384 ](https://www.ncbi.nlm.nih.gov/sites/books/NBK1384/) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ www.isuog.org/static/20863053-3657-4896-b62e823d2d2d25f2/LISA-HUI-Kelly-2021-increased-NT-pd6024.pdf ](https://www.isuog.org/static/20863053-3657-4896-b62e823d2d2d25f2/LISA-HUI-Kelly-2021-increased-NT-pd6024.pdf) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ pubmed.ncbi.nlm.nih.gov/10214502 ](https://pubmed.ncbi.nlm.nih.gov/10214502/) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ ACOG. Screening for Fetal Chromosomal Abnormalities. Practice Advisory, January 2026. ](https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2026/01/screening-for-fetal-chromosomal-abnormalities) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ www.acog.org/womens-health/faqs/amniocentesis ](https://www.acog.org/womens-health/faqs/amniocentesis) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ ACOG. Ethical Considerations for Genetic Testing and Counseling in Obstetrics and Gynecology. 2026. ](https://www.acog.org/clinical/clinical-guidance/committee-statement/articles/2026/02/ethical-considerations-for-genetic-testing-and-counseling-in-obstetrics-and-gynecology) [↩](#cite-ref-6-1 "Back to text") 7. 7. [ www.acog.org/advocacy/policy-priorities/non-invasive-prenatal-testing/current-acog-guidance ](https://www.acog.org/advocacy/policy-priorities/non-invasive-prenatal-testing/current-acog-guidance) [↩](#cite-ref-7-1 "Back to text") 8. 8. [ ACOG. Carrier Screening for Genetic Conditions. Committee Opinion No. 691. ](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions) 9. 9. [ GeneReviews. FMR1 Disorders. ](https://www.ncbi.nlm.nih.gov/books/NBK1384/) Next step Build confidence in OB/GYN with focused practice -------------------------------------------------- - Labor & delivery + postpartum essentials - Gynecology, screening, and common procedures - Review weak topics and improve faster [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features\*. No commitment. Cancel anytime. \*AI SOE Examiner is limited to 10 cases monthly for Advanced & Bundle subscribers. Explore topics: [ # Obstetrics & Gynecology ](https://mdster.com/blog?tag=obstetrics-gynecology) [ # Case Discussion ](https://mdster.com/blog?tag=case-discussion) [ # Genetic Counseling ](https://mdster.com/blog?tag=genetic-counseling) [ # Fragile X Syndrome ](https://mdster.com/blog?tag=fragile-x-syndrome) [ # Prenatal Genetics ](https://mdster.com/blog?tag=prenatal-genetics) [ # Nuchal Translucency ](https://mdster.com/blog?tag=nuchal-translucency) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Case Discussion ----------------------- [ See all ](https://mdster.com/blog?category=case-discussion) [### Diabetic Ketoacidosis Case Discussion: Insulin, Fluids, and the Transition 1 min read Oct 04, 2026 ](https://mdster.com/blog/diabetic-ketoacidosis-case-discussion-insulin-fluids-and-the-transition) [### New Weakness After Carotid Endarterectomy: An Anesthesia Case Discussion 6 min read Oct 02, 2026 ](https://mdster.com/blog/new-weakness-after-carotid-endarterectomy-an-anesthesia-case-discussion) [### Postpartum Psychosis: A Bipolar Relapse With Infant Safety at Stake 6 min read Sep 30, 2026 ](https://mdster.com/blog/postpartum-psychosis-a-bipolar-relapse-with-infant-safety-at-stake) Related Posts ------------- [ ![Diabetic Ketoacidosis Case Discussion: Insulin, Fluids, and the Transition](https://mdster.com/storage/blog/images/diabetic-ketoacidosis-case-discussion-insulin-fluids-and-the-transition.png) Case Discussion ### Diabetic Ketoacidosis Case Discussion: Insulin, Fluids, and the Transition Follow a DKA case from diagnosis through potassium replacement, dextrose, neurologic reassessment, and a safe return to subcutaneous insulin. 1 min read 0 comments ](https://mdster.com/blog/diabetic-ketoacidosis-case-discussion-insulin-fluids-and-the-transition) [ ![Applying Guidelines to Individuals in Obstetrics and Gynecology](https://mdster.com/storage/blog/images/applying-guidelines-to-individuals-in-obstetrics-and-gynecology.png) Medical Education ### Applying Guidelines to Individuals in Obstetrics and Gynecology Learn when an OB-GYN guideline fits the patient in front of you, how to reconcile conflicting recommendations, and how to make preference-sensitive decisions. 6 min read 0 comments ](https://mdster.com/blog/applying-guidelines-to-individuals-in-obstetrics-and-gynecology) [ ![New Weakness After Carotid Endarterectomy: An Anesthesia Case Discussion](https://mdster.com/storage/blog/images/new-weakness-after-carotid-endarterectomy-an-anesthesia-case-discussion.png) Case Discussion ### New Weakness After Carotid Endarterectomy: An Anesthesia Case Discussion A new focal deficit after carotid endarterectomy demands more than observation. Follow the reasoning from intraoperative shunting to urgent PACU imaging and airway assessment. 6 min read 0 comments ](https://mdster.com/blog/new-weakness-after-carotid-endarterectomy-an-anesthesia-case-discussion) [ Case Discussion ### Postpartum Psychosis: A Bipolar Relapse With Infant Safety at Stake A new mother develops insomnia, confusion, and a dangerous belief about her infant. Work through the diagnosis, immediate safeguards, treatment, and feeding decisions. 6 min read 0 comments ](https://mdster.com/blog/postpartum-psychosis-a-bipolar-relapse-with-infant-safety-at-stake) [ ![American Osteopathic Board of Obstetrics and Gynecology (Obstetrics and Gynecology Primary Written Exam): A Practical Study Plan](https://mdster.com/storage/blog/images/american-osteopathic-board-of-obstetrics-and-gynecology-obstetrics-and-gynecology-primary.png) Study Tips ### American Osteopathic Board of Obstetrics and Gynecology (Obstetrics and Gynecology Primary Written Exam): A Practical Study Plan Prepare for the AOBOG Primary Written Exam with a blueprint-based schedule, a practical question-review method, and a pacing plan for all three timed sections. 6 min read 0 comments ](https://mdster.com/blog/american-osteopathic-board-of-obstetrics-and-gynecology-obstetrics-and-gynecology-primary) [ ![Varicella Exposure in a Child With ALL: Prophylaxis and Vaccines](https://mdster.com/storage/blog/images/varicella-exposure-in-a-child-with-all-prophylaxis-and-vaccines.png) Case Discussion ### Varicella Exposure in a Child With ALL: Prophylaxis and Vaccines A child receiving ALL maintenance therapy is exposed to chickenpox at home. Work through the one-dose immunity caveat, postexposure prophylaxis, and vaccine decisions. 7 min read 0 comments ](https://mdster.com/blog/varicella-exposure-in-a-child-with-all-prophylaxis-and-vaccines) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ Download on the App Store ](https://apps.apple.com/app/id6759168258) [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Curriculum](https://mdster.com/curriculum) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) [ ](https://apps.apple.com/app/id6759168258) [ ](https://play.google.com/store/apps/details?id=com.mdster.app) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept